Skip to main content
JW LIFESCIENCE CORPORATION logo

JW LIFESCIENCE CORPORATION — Investor Relations & Filings

Ticker · 234080 ISIN · KR7234080000 KO Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2025-02-25 Proxy Solicitation & In…
Country KR South Korea
Listing KO 234080

About JW LIFESCIENCE CORPORATION

https://www.jw-lifescience.co.kr/lifesc…

JW LIFESCIENCE CORPORATION is a specialized manufacturer focused on the development and production of infusion solutions. The company's product portfolio includes a comprehensive range of intravenous (IV) fluids, from basic solutions to advanced nutrient infusions containing essential components such as amino acids, lipids, proteins, vitamins, and minerals. A key area of innovation is the development of high-value-added products, including multi-chambered infusion solutions. The company operates world-class manufacturing facilities and maintains dedicated research and development centers to support its commitment to producing high-quality medical fluids for patient treatment.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for JW Life Science. It contains the agenda for the upcoming 31st Annual General Meeting, including items for approval such as financial statements, director appointments, and dividend proposals. It also includes detailed proxy information, board activity reports, and financial summaries. This document is a formal solicitation of shareholder participation and proxy voting for the meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-02-25 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains details on the meeting agenda (financial statement approval, director appointments, remuneration limits, etc.), proxy solicitation procedures, and voting methods. This falls under the 'Proxy Solicitation & Information Statement' category.
2025-02-25 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Change in Sales or Profit/Loss Structure of 30% or more'. This is a standard preliminary earnings announcement (Earnings Release) provided by a company to disclose significant changes in financial performance before the final audited annual report is published. It contains key financial highlights, comparative data, and reasons for the change, fitting the definition of an Earnings Release (ER). FY 2024
2025-02-19 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from JW Life Science regarding the decision to pay a cash dividend. It specifies the dividend amount per share, the total dividend amount, the dividend record date, and the expected date of the general meeting of shareholders. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2025-02-10 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by JW Life Science. It outlines the date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and details regarding electronic voting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2025-02-10 Korean
매출액또는손익구조30%(대규모법인15%)미만변경(자율공시)
Earnings Release Classification · 100% confidence The document is a regulatory filing from JW Life Science regarding a change in sales or profit/loss structure (less than 30%). It provides preliminary financial results (revenue, operating profit, net income) for the fiscal year compared to the previous year. Since this is an initial announcement of financial results (key highlights) and explicitly states these are preliminary figures subject to audit, it falls under the Earnings Release (ER) category. FY 2024
2025-02-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.